Dellavedova L, Carletto M, Faggioli P, Sciascera A, Del Sole A, Mazzone A, Maffioli L S
PET/CT Center - Nuclear Medicine Department, Ospedale Civile di Legnano, Via Papa Giovanni Paolo II, 1, 20025, Legnano (MI), Italy.
Department of Health Sciences, University of Milan, Milan, Italy.
Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):340-348. doi: 10.1007/s00259-015-3148-9. Epub 2015 Aug 8.
The aim of this study was to analyse if the result of a baseline (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan, in large-vessel vasculitis (LVV) patients, is able to predict the course of the disease, not only in terms of presence/absence of final complications but also in terms of favourable/complicated progress (response to steroid therapy, time to steroid suspension, relapses, etc.).
A total of 46 consecutive patients, who underwent (18)F-FDG PET/CT between May 2010 and March 2013 for fever of unknown origin (FUO) or suspected vasculitis (before starting corticosteroid therapy), were enrolled. The diagnosis of LVV was confirmed in 17 patients. Considering follow-up results, positive LVV patients were divided into two groups, one characterized by favourable (nine) and the other by complicated progress (eight), on the basis of presence/absence of vascular complications, presence/absence of at least another positive PET/CT during follow-up and impossibility to comply with the tapering schedule of the steroid due to biochemical/symptomatic relapse. Vessel uptake in subjects of the two groups was compared in terms of intensity and extension. To evaluate the extent of active disease, we introduced two volume-based parameters: "volume of increased uptake" (VIU) and "total lesion glycolysis" (TLG). The threshold used to calculate VIU on vessel walls was obtained by the "vessel to liver" ratio by means of receiver-operating characteristic analysis and was set at 0.92 × liver maximum standardized uptake value in each patient.
Measures of tracer uptake intensity were significantly higher in patients with complicated progress compared to those with a favourable one (p < 0.05). Measures of disease extension were even more significant and TLG emerged as the best parameter to separate the two groups of patients (p = 0.01).
This pilot study shows that, in LVV patients, the combined evaluation of the intensity and the extension of FDG vessel uptake at diagnosis can predict the clinical course of the disease, separating patients with favourable or complicated progress.
本研究旨在分析大血管血管炎(LVV)患者基线(18)F-氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)/CT扫描结果是否不仅能够预测疾病的最终并发症情况,还能预测疾病的进展是良好还是复杂(对类固醇治疗的反应、停用类固醇的时间、复发情况等)。
纳入2010年5月至2013年3月期间因不明原因发热(FUO)或疑似血管炎(在开始使用皮质类固醇治疗前)接受(18)F-FDG PET/CT检查的46例连续患者。17例患者确诊为LVV。根据随访结果,将确诊为LVV的患者分为两组,一组疾病进展良好(9例),另一组进展复杂(8例),分组依据为是否存在血管并发症、随访期间是否至少有另一次阳性PET/CT检查结果以及是否因生化/症状复发而无法遵守类固醇药物的减量方案。比较两组患者血管摄取的强度和范围。为评估活动性疾病的程度,我们引入了两个基于体积的参数:“摄取增加体积”(VIU)和“总病变糖酵解”(TLG)。通过受试者操作特征分析,利用“血管与肝脏”比值获得计算血管壁VIU的阈值,该阈值设定为每位患者肝脏最大标准化摄取值的0.92倍。
与进展良好的患者相比,进展复杂的患者示踪剂摄取强度测量值显著更高(p < 0.05)。疾病范围测量值差异更为显著,TLG成为区分两组患者的最佳参数(p = 0.01)。
这项初步研究表明,在LVV患者中,诊断时对FDG血管摄取的强度和范围进行综合评估可以预测疾病的临床进程,区分进展良好或复杂的患者。